Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Clinical trial NCT06851442 · TERMINATED
Trial details
- NCT number
- NCT06851442
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-16
- Primary completion
- 2025-11-20
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.